Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.
CSPC Innovation Pharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical Group, released its unaudited financial results for the nine months ending September 30, 2025. The report highlights a 7.71% increase in operating revenue compared to the previous year, but also reveals significant net losses and a negative cash flow from operating activities. These financial challenges may impact the company’s operations and market positioning, urging caution among shareholders and potential investors.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a company in the pharmaceutical industry, focusing on the development and production of innovative drugs. Its market focus includes both domestic and international markets, with a subsidiary, CSPC Innovation Pharmaceutical Co., Ltd., listed on the ChiNext of Shenzhen Stock Exchange.
YTD Price Performance: 69.79%
Average Trading Volume: 173,272,664
Technical Sentiment Signal: Buy
Current Market Cap: HK$90.76B
For detailed information about 1093 stock, go to TipRanks’ Stock Analysis page.